ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2018

Oct 24, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2018-10-19

Reporting Person: Leone Peter Brian (VP, Strategic Bus. Initiatives)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-19	Common Stock	M	30000	$2.79	Acquired	160000	Direct
2018-10-19	Common Stock	M	34375	$6.15	Acquired	194375	Direct
2018-10-19	Common Stock	M	66762	$7.75	Acquired	261137	Direct
2018-10-19	Common Stock	S	131137	$13.49	Disposed	130000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-19	Stock Options	$2.79	M	30000	Disposed	2023-07-20	Common Stock (30000)	Direct
2018-10-19	Stock Options	$6.15	M	34375	Disposed	2026-01-01	Common Stock (34375)	Direct
2018-10-19	Stock Options	$7.75	M	66762	Disposed	2025-03-06	Common Stock (66762)	Direct

Footnotes

F1: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.10 to $13.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

F3: Represents first vesting date. Option vests over four years from date of grant.